JP2017524721A - Ｎｍｄａ調節剤を使用するうつ病の治療方法 - Google Patents

Ｎｍｄａ調節剤を使用するうつ病の治療方法 Download PDF

Info

Publication number
JP2017524721A
JP2017524721A JP2017507973A JP2017507973A JP2017524721A JP 2017524721 A JP2017524721 A JP 2017524721A JP 2017507973 A JP2017507973 A JP 2017507973A JP 2017507973 A JP2017507973 A JP 2017507973A JP 2017524721 A JP2017524721 A JP 2017524721A
Authority
JP
Japan
Prior art keywords
weeks
patient
depression
glyx
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017507973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524721A5 (OSRAM
Inventor
ロン バーチ
ロン バーチ
Original Assignee
ノーレックス インコーポレイテッド
ノーレックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノーレックス インコーポレイテッド, ノーレックス インコーポレイテッド filed Critical ノーレックス インコーポレイテッド
Publication of JP2017524721A publication Critical patent/JP2017524721A/ja
Publication of JP2017524721A5 publication Critical patent/JP2017524721A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017507973A 2014-08-14 2015-08-13 Ｎｍｄａ調節剤を使用するうつ病の治療方法 Pending JP2017524721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14
US62/037,374 2014-08-14
PCT/US2015/045071 WO2016025721A1 (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020076468A Division JP2020128391A (ja) 2014-08-14 2020-04-23 Ｎｍｄａ調節剤を使用するうつ病の治療方法

Publications (2)

Publication Number Publication Date
JP2017524721A true JP2017524721A (ja) 2017-08-31
JP2017524721A5 JP2017524721A5 (OSRAM) 2018-09-20

Family

ID=55304631

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017507973A Pending JP2017524721A (ja) 2014-08-14 2015-08-13 Ｎｍｄａ調節剤を使用するうつ病の治療方法
JP2020076468A Pending JP2020128391A (ja) 2014-08-14 2020-04-23 Ｎｍｄａ調節剤を使用するうつ病の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020076468A Pending JP2020128391A (ja) 2014-08-14 2020-04-23 Ｎｍｄａ調節剤を使用するうつ病の治療方法

Country Status (18)

Country Link
US (1) US20170296616A1 (OSRAM)
EP (1) EP3180015A4 (OSRAM)
JP (2) JP2017524721A (OSRAM)
KR (1) KR20170040351A (OSRAM)
CN (1) CN106659763A (OSRAM)
AU (2) AU2015301650A1 (OSRAM)
BR (1) BR112017002930A2 (OSRAM)
CA (1) CA2957937A1 (OSRAM)
CL (1) CL2017000378A1 (OSRAM)
CO (1) CO2017002356A2 (OSRAM)
IL (1) IL250557A0 (OSRAM)
MX (1) MX2017002052A (OSRAM)
PH (1) PH12017500275A1 (OSRAM)
RU (1) RU2017107033A (OSRAM)
SG (2) SG10201810016XA (OSRAM)
UA (1) UA123623C2 (OSRAM)
WO (1) WO2016025721A1 (OSRAM)
ZA (1) ZA201701526B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512857A (ja) * 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
EP3720464A1 (en) * 2017-12-05 2020-10-14 Naurex Inc. Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316954A1 (en) * 2009-10-05 2013-11-28 Northwestern University Methods of Treating Depression and Other Related Diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
HRP20140784T1 (hr) * 2009-10-05 2014-10-10 Northwestern University Glyx-13 za uporabu u postupku tretiranja refraktornih depresija
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316954A1 (en) * 2009-10-05 2013-11-28 Northwestern University Methods of Treating Depression and Other Related Diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL M. MESSER; ET AL: "MAINTENANCE KETAMINE TREATMENT PRODUCES LONG-TERM RECOVERY FROM DEPRESSION", PRIMARY PSYCHIATRY, JPN5017007040, 21 May 2013 (2013-05-21), pages 48 - 50, ISSN: 0004176191 *
MOSKAL,JR; ET AL: "GLYX-13, AN NMDA RECEPTOR GLYCINE SITE FUNCTIONAL PARTIAL AGONIST ENHANCES COGNITION AND 以下備考", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. VOL:23,NR:2, JPN5017007039, 20 November 2013 (2013-11-20), pages 243 - 254, ISSN: 0004176190 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512857A (ja) * 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法

Also Published As

Publication number Publication date
KR20170040351A (ko) 2017-04-12
EP3180015A4 (en) 2018-02-14
EP3180015A1 (en) 2017-06-21
WO2016025721A1 (en) 2016-02-18
AU2015301650A1 (en) 2017-03-23
CA2957937A1 (en) 2016-02-18
IL250557A0 (en) 2017-03-30
BR112017002930A2 (pt) 2017-12-05
SG10201810016XA (en) 2018-12-28
CO2017002356A2 (es) 2017-06-09
RU2017107033A3 (OSRAM) 2019-02-12
ZA201701526B (en) 2018-05-30
US20170296616A1 (en) 2017-10-19
MX2017002052A (es) 2018-08-15
JP2020128391A (ja) 2020-08-27
CN106659763A (zh) 2017-05-10
PH12017500275A1 (en) 2017-07-03
RU2017107033A (ru) 2018-09-14
SG11201701134XA (en) 2017-03-30
AU2020203165A1 (en) 2020-06-04
UA123623C2 (uk) 2021-05-05
CL2017000378A1 (es) 2017-11-03

Similar Documents

Publication Publication Date Title
JP2020128391A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
JP2022159322A (ja) Ｎｍｄａｒ調節化合物の組合せ
US20160002292A1 (en) Methods of treating depression and other related diseases
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
JP6862404B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
CN103619330A (zh) 用于治疗糖尿病的选择性雄激素受体调节剂
JP2010530867A (ja) うつ病の治療
WO2011131705A1 (en) Treatment of multiple sclerosis with masitinib
AU2019264583A1 (en) Treating brain disorders and biomarkers related thereto
TWI457123B (zh) ４－｛３－［順式－六氫環戊并［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺與ｎｍｄａ受體拮抗劑之新結合及包含彼等之醫藥組合物
RU2013149635A (ru) Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря
WO2014065341A1 (ja) 筋萎縮性側索硬化症治療剤
JP2021522271A (ja) 虚弱および加齢を改善するための方法
JP7527662B2 (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
CN1968693A (zh) 包含乙酰胆碱酯酶抑制剂与5－取代－3－∴二唑基－1,6－萘啶－2(1h)－酮衍生物组合的药物
CN1247578C (zh) 含有2－芳基－8－氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
RU2013149634A (ru) Комбинации троспия и стимуляторов слюноотделения для лечения гиперактивного мочевого пузыря
US12502371B2 (en) Drug for treating and preventing dementia
JP2024030188A (ja) 女性のうつ症状を改善するための医薬組成物
JP6216913B1 (ja) 医薬組成物
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
JP2017088584A (ja) 医薬組成物
CZ2006623A3 (cs) Kombinace deramciklanu a opioidů jako analgetik
AU2016204151A1 (en) Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment
JP2005126343A (ja) 免疫抑制用薬剤組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191223